At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 504 enrolled
Drug / intervention
Febuxostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout
In Brief
A Phase 3 clinical trial evaluating Febuxostat and Allopurinol for Gout. Completed, enrolled 504 participants.
Detailed Summary
The purpose of this study is to compare febuxostat allopurinol in subjects with gout.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout
Countries--
CollaboratorsQingdao Shengbang Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
Primary CompletionOct 2013
First PostedMar 2014
TodayJul 2026
First PostedMar 10, 2014
Enrollment StartJul 1, 2011
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.3 years ago
Interventions
Febuxostatdrug
Allopurinoldrug